Compare FNWB & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | VRCA |
|---|---|---|
| Founded | 1923 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.3M | 88.0M |
| IPO Year | 2012 | 2018 |
| Metric | FNWB | VRCA |
|---|---|---|
| Price | $11.10 | $5.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $13.50 | ★ $17.00 |
| AVG Volume (30 Days) | 18.3K | ★ 102.4K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $176,000.00 | ★ $35,577,000.00 |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | $94.44 |
| P/E Ratio | $281.50 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $7.05 | $3.28 |
| 52 Week High | $12.52 | $9.82 |
| Indicator | FNWB | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 50.26 |
| Support Level | $10.88 | $4.52 |
| Resistance Level | $11.51 | $6.22 |
| Average True Range (ATR) | 0.24 | 0.43 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 24.91 | 49.60 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.